SynthesisEuropean journal of drug metabolism and pharmacokinetics2025
Factors Affecting Pharmacokinetics of Sunitinib and Its Metabolite, SU12662: A Systematic Review of Population Pharmacokinetic Studies.
Synthesis in European journal of drug metabolism and pharmacokinetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Review on Nanocarrier-Based Strategies for Sunitinib Delivery: Advances in Pharmacokinetic Enhancement and Targeted Theranostics.AAPS PharmSciTech · 2026Review
- Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.Clinical pharmacokinetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveSunitinib malate is used to treat advanced renal cell carcinoma, gastrointestinal stromal, and pancreatic tumors. Wide variability in drug exposure is reported for both sunitinib and its active metabolite (SU12662). This review aimed to summarize reported population pharmacokinetics studies of sunitinib and to identify the factors affecting the pharmacokinetics of sunitinib and SU12662.
methodsA systematic search was undertaken using Scopus, Web of Science, and PubMed databases following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies were included in the review if population pharmacokinetic modeling approach was used for sunitinib and/or SU12662 in adult and/or pediatric population. Data quality was assessed using the percent compliance rate of each study.
resultsA total of 1820 articles were retrieved, and subsequently, 14 studies that met the inclusion criteria were included in the systematic review. Most of the studies reported two-compartment model with first-order absorption and elimination to describe sunitinib and SU12662. Body surface area, age, sex, ethnicity, tumor type, and ABCB1 and ABCG2 genotype were the significant covariates that affected the pharmacokinetics of sunitinib and SU12662.
conclusionsAccording to the published data from the reported studies, various covariates alter sunitinib and SU12662 exposure and thus have the potential to influence the clinical outcome of sunitinib treatment. Predictive performance assessment of these published models should be performed before implementing these models during the routine clinical practice. The summarized significant covariates affecting pharmacokinetics (PK) of sunitinib and SU12662 will facilitate model-informed precision dosing of sunitinib therapy in a clinical setting.
Indexed as
Identifiers
41023290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.